LinkedIn Icon Twitter Icon
March 19-21, 2018 | Boston, MA

Day One
Tuesday, March 20 2018

Day Two
Wednesday, March 21 2018

Chair’s Opening Remarks

  • Bernard Fox Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Providence Cancer Center

Pioneering Rational Combination Approaches

Keynote: Enhancing Patient Outcomes With Pembrolizumab In Combination Strategies

  • Roger Dansey SVP, Global Clinical Development Oncology, Merck


  • Investigating diverse combination strategies with pembrolizumab
  • Critical considerations for developing effective combination strategies – improving outcomes and maintaining tolerability
  • Understanding clinical combinations: biologic rationale and expecting the unexpected

Keynote: Addressing the Tidal Wave of Cancer Immunotherapy Combinations Through Innovative Trial Designs

  • Bill Grossman Group Medical Director, Cancer Immunotherapy, Genentech


  • Highlighting the opportunity for novel clinical trial designs to address developmental challenges in the cancer immunotherapy space
  • Investigating the current state of cancer immunotherapy combination development across the industry
  • Understanding key clinical development challenges for cancer immunotherapy combination development
  • Developing a combination platform to increase the speed of identification of transformative signals
  • Examples of novel clinical trial designs to address combination development challenges

Speed Networking & Morning Refreshments

Identifying Translationally Relevant Biomarkers

11.00 Transforming Translational Research: CANscript™ - A Better Predictive Model For Oncology


  • Developing and clinically validating a fully human ex vivo platform technology (CANscript™)
  • Using patient material (tumor, autologous ligands and PBMC) to explore the mechanism of action and predict efficacy for clinically-directed compounds in a modalityagnostic way using phenotypic effects
  • Explore how CANscript was used to model the effect of checkpoint inhibition in HNSCC as a means of identifying predictors of clinical response and uncovering mechanisms of resistance

Mark Paris, Associate Director, Translational Applications, Mitra Biotech

11.30 From Bench to Clinic: Developing Biomarker Strategies for Immunotherapy Combinations

  • Using a deep understanding of target biology to narrow the list of candidate biomarkers that relate to the mechanism of action of a given drug
  • Challenges in interpreting biomarker data from combination studies

Jennifer Mataraza, Senior Investigator ll, Group Leader, Translational Immuno-Oncology, Novartis

12.00 Pharmacodynamic & Predictive Biomarkers in Clinical Development of JTX-2011, an ICOS Agonist

  • Identifying two important biomarkers for clinical development through preclinical efficacy studies
  • Using a pharmacodynamic biomarker in Phase 1 to identify the recommended Phase 2 dose
  • Selecting indications and enriching patient enrolment in Phase 2 using a potential predictive biomarker

Beth Trehu, CMO, Jounce

12.30 Lunch & Networking

‘Extreme Personalized Medicine’ – The Future of Immuno-Oncology?

14.00 Beyond PD-L1: Understanding Novel Translational Biomarkers to Stratify Patients Effectively for Personalized Cancer Immunotherapy

  • Analyzing patient level biomarker stratification approaches to compare novel immunotherapy combinations more accurately
  • Combining new omics technologies to give a comprehensive picture of the tumor microenvironment to guide immunotherapy applications
  • Evaluating large data sets to discover gene signatures that will enhance the predictability of clinical outcomes

Jianda Yuan, Director, Translational Immuno-Oncology Research, Merck

14.30 Integrative Analyses of Microbiota, Environment, and Tumor Immunity for Personalizing Immunotherapy

  • Broadening the scope – understanding environmental and microbial factors that affect patient responses to immunotherapy
  • Analyzing human samples to investigate the influence of exposome (exposures) and microbiome on immune responses
  • Examining factors like microsatellite instability and neoantigen load that affect immunotherapy outcomes

Shuji Ogino, Professor, Dana-Farber Cancer Institute

Achieving Preclinical & Clinical Success Through Rational Combinations

11.00 Investigating Combination Strategies to Overcome Mechanisms of Resistance to Checkpoint Modulators

  • Assessing our understanding of mechanisms of resistance and how patients develop resistance to checkpoint inhibitors
  • Evaluating how rational combination approaches may overcome resistance
  • Exploring clinical combination trials to overcome resistance at various stages of the immune cycle

Osama Rahma, Assistant Professor of Medicine, Dana-Farber Cancer Institute

11.30 Investigating the Potential of TIM-3 & LAG-3 in the Context of Novel Combination Strategies

  • Understanding how substantial numbers of patients in all tumor types do not respond to anti-PD1/L1 therapy, and patients eventually progress on therapy, suggesting other mechanisms of immune escape persist across tumors
  • Learning about theLAG-3 and TIM-3 agents that are in development to address de novo refractory tumors and treatment emergent resistance
  • Providing an update on role of LAG-3 and TIM-3 in tumors and status of TSR-033 (anti-LAG3) and TSR-22 (anti-TIM3)

Jeffrey Hanke, CSO & EVP, Research & Development, TESARO

12.00 Rational IO/IO & IO/ADC Combinations to Modulate the Immune System

  • Using the CD27 agonist antibody, Varlilumab, in combination with anti-PD1 antibody, Nivolumab, in advanced cancer patients
  • Rationale, preclinical and early clinical data combining the anti-gpNMB ADC Glembatumumab Vedotin with immunotherapy
  • Rationale and preclinical data for using a CD40 agonist antibody in IO combinations

Chris Turner, VP, Clinical Science, Celldex

12.30 Lunch & Networking

Driving Novel Combination Approaches Into The Clinic

14.00 Innate & Adaptive Integrin-Targeted Combination Immunotherapy

  • Developing an engineered integrin-binding peptide-Fc fusion that targets and recruits immune cell effector functions to tumors
  • Invoking innate and adaptive arms of the immune system through the co-administration of the peptide-Fc fusion and an immune modulator, such as a checkpoint blockade inhibitor, results in significant control of tumor growth

Jennifer Cochran, Associate Professor, Bioengineering, Stanford University

14.30 Investigating Combinations Involving Standard of Care Therapeutics & Immunomodulatory Agents

  • Gaining a mechanistic understanding of the role of radiotherapy in priming the immune system for checkpoint modulation
  • Case studies investigating the successful combination of these agents – what elements of the combination played a role in success?

Anna Tafuri, Global Early Clinical Lead, Bayer

Afternoon Refreshments & Poster Viewing

Turning Up the Heat on Cold Tumors by Engaging the Broader Tumor Microenvironment

Tumor & Host Factors Influencing the Tumor Microenvironment & Response to Checkpoint Blockade

  • Jason Luke Assistant Professor of Medicine, University of Chicago


  • Review the T cell-inflamed and non-T cell-inflamed tumor micro-environment as a model for predicting rational immunotherapy combinations
  • Interrogate patient level gene expression profiling as a route to “personalized” combination immunotherapy
  • Describe the impact of the commensal microbiome on anti-PD1 responsiveness in melanoma

Evaluating the Role of Stromal Cells & TGFβ Signalling in the Resistance to Atezolizumab


  • Understanding the role of stromal cells in the tumor microenvironment and the effect of cross-talk with immune cells
  • Analyzing factors correlating with resistance to atezolizumab and reverse translating this information to provide meaningful preclinical insights
  • Building tools to study mesenchymal cells and their impact on immuno-oncology across tumor types

Chair’s Closing Remarks

  • Bernard Fox Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Providence Cancer Center